Lab tests have shown promise, namely that BrachySil is very well retained within liver tissue with little or no radioactivity reaching surrounding tissue or the blood stream, and that therapy killed tissue within a very well-defined radius of application.
Human trials have begun in Singapore. Currently there are two liver cancer patients being treated, with plans for ten more. Results are expected by October 2004, with the product reaching market in 2006. Long term plans are to target also brain and pancreas tumors.
There are some interesting photos at the pSivida site of the first patient receiving treatment.